Targeting cancer-initiating cell drug-resistance: A Sroadmap to a new-generation of cancer therapies?

Research output: Contribution to journalArticlepeer-review

Abstract

The occurrence of drug resistance in oncology accounts for treatment failure and relapse of diverse tumor types. Cancers contain cells at various stages of differentiation together with a limited number of 'cancer-initiating cells' able to self-renew and divide asymmetrically, driving tumorigenesis. Cancer-initiating cells display a range of self-defense systems that include almost all mechanisms of drug-resistance. Different molecular pathways and markers, identified in this malignant sub-population, are becoming targets for novel compounds and for monoclonal antibodies, which may be combined with conventional drugs. These interventions might eliminate drug-resistant cancer-initiating cells and lead to remission or cure of cancer patients.

Original languageEnglish
Pages (from-to)435-442
Number of pages8
JournalDrug Discovery Today
Volume17
Issue number9-10
DOIs
Publication statusPublished - May 2012

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Fingerprint

Dive into the research topics of 'Targeting cancer-initiating cell drug-resistance: A Sroadmap to a new-generation of cancer therapies?'. Together they form a unique fingerprint.

Cite this